A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder.
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2015
At a glance
- Drugs Ganaxolone (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Marinus Pharmaceuticals
- 20 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014, according to ClinicalTrials.gov record.
- 15 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.